Improving cancer therapy using advanced gene editing techniques
Multiplexed nanoparticle delivery to increase CRISPR/Cas gene editing for enhanced cancer therapy
['FUNDING_R01'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-11023076
This study is exploring a new way to improve cancer treatment by using special tiny particles to deliver gene-editing tools directly to tumors, which could help make therapies more effective for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-11023076 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing cancer treatment by improving the delivery of CRISPR/Cas gene editing technology to solid tumors. It utilizes a novel approach involving multiplexed lipid nanoparticles that can co-deliver multiple therapeutic agents directly to tumor tissues. By targeting the unique mechanical properties of the tumor microenvironment, this method aims to increase the effectiveness of gene editing in cancer cells. Patients may benefit from a more effective cancer therapy that can precisely target and modify cancer-related genes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors, particularly those with hepatocellular carcinoma or non-small cell lung cancer.
Not a fit: Patients with non-solid tumors or those who do not have cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that specifically target and modify cancer genes, potentially improving patient outcomes.
How similar studies have performed: Other research has shown promise in using nanoparticle delivery systems for gene editing, indicating that this approach has potential for success.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SIEGWART, DANIEL JOHN — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: SIEGWART, DANIEL JOHN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy